These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 21110238)

  • 1. Evaluating the cost-effectiveness of self-monitoring of blood glucose in type 2 diabetes patients on oral anti-diabetic agents.
    Pollock RF; Valentine WJ; Goodall G; Brändle M
    Swiss Med Wkly; 2010; 140():w13103. PubMed ID: 21110238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Self-monitoring of blood glucose (SMBG) for type 2 diabetes patients treated with oral anti-diabetes drugs and with a recent history of monitoring: cost-effectiveness in the US.
    Tunis SL; Minshall ME
    Curr Med Res Opin; 2010 Jan; 26(1):151-62. PubMed ID: 19919376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
    Tunis SL; Willis WD; Foos V
    Curr Med Res Opin; 2010 Jan; 26(1):163-75. PubMed ID: 19919377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Self-monitoring of blood glucose in type 2 diabetes: cost-effectiveness in the united states.
    Tunis SL; Minshall ME
    Am J Manag Care; 2008 Mar; 14(3):131-40. PubMed ID: 18333705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous glucose monitoring for self-management of diabetes in people living with type 2 diabetes mellitus on basal insulin therapy: A microsimulation model and cost-effectiveness analysis from a US perspective with relevance to Medicaid.
    Frank J; Son D; Szafranski K; Poon Y
    J Manag Care Spec Pharm; 2024 Sep; 30(9):917-928. PubMed ID: 39109990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes.
    Palmer AJ; Dinneen S; Gavin JR; Gray A; Herman WH; Karter AJ
    Curr Med Res Opin; 2006 May; 22(5):861-72. PubMed ID: 16709308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of self-monitoring of blood glucose (SMBG) for patients with type 2 diabetes and not on insulin: impact of modelling assumptions on recent Canadian findings.
    Tunis SL
    Appl Health Econ Health Policy; 2011 Nov; 9(6):351-65. PubMed ID: 21892840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
    Valentine WJ; Palmer AJ; Lammert M; Langer J; Brändle M
    Clin Ther; 2011 Nov; 33(11):1698-712. PubMed ID: 22018679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type II diabetes in France.
    Alshannaq H; Pollock RF; Joubert M; Ahmed W; Norman GJ; Lynch PM; Roze S
    J Comp Eff Res; 2024 Mar; 13(3):e230174. PubMed ID: 38294332
    [No Abstract]   [Full Text] [Related]  

  • 10. Real-time continuous glucose monitoring vs. self-monitoring of blood glucose: cost-utility in South Korean type 2 diabetes patients on intensive insulin.
    Kim JY; Ilham S; Alshannaq H; Pollock RF; Ahmed W; Norman GJ; Jin SM; Kim JH
    J Med Econ; 2024; 27(1):1245-1252. PubMed ID: 39275990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting.
    Brändle M; Goodall G; Erny-Albrecht KM; Erdmann E; Valentine WJ
    Swiss Med Wkly; 2009 Mar; 139(11-12):173-84. PubMed ID: 19330561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is self-monitoring of blood glucose appropriate for all type 2 diabetic patients? The Fremantle Diabetes Study.
    Davis WA; Bruce DG; Davis TM
    Diabetes Care; 2006 Aug; 29(8):1764-70. PubMed ID: 16873777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of G5 Mobile continuous glucose monitoring device compared to self-monitoring of blood glucose alone for people with type 1 diabetes from the Canadian societal perspective.
    Chaugule S; Graham C
    J Med Econ; 2017 Nov; 20(11):1128-1135. PubMed ID: 28745578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-economic analysis of real-time continuous glucose monitoring in people with Type 1 diabetes.
    Roze S; Saunders R; Brandt AS; de Portu S; Papo NL; Jendle J
    Diabet Med; 2015 May; 32(5):618-26. PubMed ID: 25483869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a U.K. perspective.
    Roze S; Smith-Palmer J; Valentine WJ; Cook M; Jethwa M; de Portu S; Pickup JC
    J Med Econ; 2016; 19(3):236-42. PubMed ID: 26510389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term cost-effectiveness of Dexcom G6 real-time continuous glucose monitoring system in people with type 1 diabetes in Australia.
    Isitt JJ; Roze S; Tilden D; Arora N; Palmer AJ; Jones T; Rentoul D; Lynch P
    Diabet Med; 2022 Jul; 39(7):e14831. PubMed ID: 35298036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost impact of blood glucose self-monitoring on complications of type 2 diabetes: a Swiss perspective (ROSSO study No.11).
    Weber C; Schneider B; Lodwig V; Holm MV; Neeser K
    Swiss Med Wkly; 2007 Oct; 137(39-40):545-50. PubMed ID: 17990145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term Cost-Effectiveness of Dexcom G6 Real-time Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Patients With Type 1 Diabetes in the U.K.
    Roze S; Isitt J; Smith-Palmer J; Javanbakht M; Lynch P
    Diabetes Care; 2020 Oct; 43(10):2411-2417. PubMed ID: 32647050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type 2 diabetes in Canada.
    Alshannaq H; Isitt JJ; Pollock RF; Norman GJ; Cogswell G; Lynch PM; Roze S
    J Comp Eff Res; 2023 Oct; 12(10):e230075. PubMed ID: 37668608
    [No Abstract]   [Full Text] [Related]  

  • 20. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK.
    Valentine WJ; Bottomley JM; Palmer AJ; Brändle M; Foos V; Williams R; Dormandy JA; Yates J; Tan MH; Massi-Benedetti M;
    Diabet Med; 2007 Sep; 24(9):982-1002. PubMed ID: 17593245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.